Delving into the Latest Updates on Linagliptin with Synapse

Elevated levels of dipeptidyl-peptidase (DPP-4) enzyme, associated with accelerated bone resorption, are linked to both post-menopausal osteoporosis (PMO) and glucocorticoid-induced osteoporosis (GIO). Consequently, DPP-4 inhibitors, a class of anti-diabetic drugs, emerge as potential candidates for repurposing as anti-osteoporotic agents. In this study, we explored the effect of 4-week treatment with linagliptin (a DPP-4 inhibitor) and its combination with metformin on PMO and GIO in mice. PMO was induced in Balb/c mice by injecting 4-vinyl cyclohexene diepoxide (VCD), 160 mg/kg, ip for 15 days while GIO was induced by administering dexamethasone (DEX) 5 mg/kg, ip for 21 days. A significant improvement in bone architectural parameters and bone mineral density (BMD) was observed following the linagliptin-metformin combination, which was consistent with the altered bone turnover markers i.e., increased ALP, osteocalcin, BMP-2, and reduced serum calcium, TRAP, sclerostin and pro-inflammatory cytokines. Results from bone immunohistochemistry (IHC) demonstrated that the combination led to an increase in immunopositive OPG cells, while RANKL expression was diminished. Linagliptin, however, demonstrated only partial improvement in the PMO model. Conversely, in the GIO model, linagliptin did not show a significant effect except for improved BMD and sclerostin levels. Treatment with metformin did not show significant changes in either model. These findings suggest that the combination of linagliptin with metformin could alleviate the PMO and GIO, possibly through targeting AMPK and Wnt signaling pathway and thereby modulating BMP-2, sclerostin and RANKL/OPG.

01 Sep 2025·BIOMATERIALS

Regulation of osteoimmune microenvironment via functional dynamic hydrogel for diabetic bone regeneration

Article

Author: Qin, Yi ; Yu, Lei ; Li, Wenming ; Xia, Wenyu ; Geng, Dechun ; Yin, Weiling ; Li, Wenhao ; Zhang, Wei ; Yang, Peng ; Ding, Fan ; Meng, Fanwen ; Ge, Gaoran ; Wu, Zebin ; Chen, Xu ; Bai, Jiaxiang

Bone regeneration and repair face formidable challenges under diabetic conditions, primarily due to the disruption of macrophage polarization induced by diabetes and the inflammatory imbalance within the bone microenvironment. We have developed a novel dynamic hydrogel system (AG-CD@LINA), constructed through the coordination crosslinking of thiolated gelatin (SH-Gelatin) and gold ions (Au³⁺), followed by grafting with cyclodextrin to load the ligand linagliptin. This hydrogel effectively inhibits the formation of M1 macrophages and the expression of pro-inflammatory cytokines by gradually releasing linagliptin. Simultaneously, it promotes the formation of M2 macrophages and the expression of anti-inflammatory cytokines, thus improving the inflammatory microenvironment of diabetic bone defects. Consequently, it facilitates the migration of mesenchymal stem cells and angiogenic cells, augments osteogenic activity, and promotes vascularization, collectively accelerating the regeneration of diabetic bone tissue. Mechanistically, polarization occurs through the TLR3-NF-κB signaling pathway. In vivo experiments demonstrate that the in-situ injection of the hydrogel enhances the regeneration of bone tissue and the restoration of bone structure in diabetic bone defects, effectively modulating local inflammation and promoting vascular formation. This study suggests that functionalized dynamic hydrogels can improve the inflammatory microenvironment by regulating in situ macrophage polarization, thereby facilitating the reconstruction of bone microstructure. This approach represents a promising novel therapeutic strategy for diabetic bone defects.

37

News (Medical) associated with Linagliptin

09 May 2025

·pharma.economictimes.indiatimes.com

NPPA sets Empagliflozin combos retail prices, as domestic brands initiate generic contest

New Delhi: As domestic brands in India began introducing their generic versions of key anti-diabetic medicine empagliflozin following the expiry of its patent, the National Pharmaceutical Pricing Authority (NPPA), has fixed the retail prices of the drug combinations and different dosage strengths. Issuing a gazette notification, the Ministry of Chemicals and Fertilizers and the country’s drug price regulator announced that “based on the decision of 132nd Authority meeting dated 29.4.2025 the authority has fixed retail prices of 84 formulations under Drugs (Prices Control) Order, 2013.” The price list attached with the official notification includes around 36 variants of empagliflozin, linagliptin and metformin hydrochloride Fixed-Dose Combinations (FDC) of various brands and manufacturers. Empagliflozin, indicated for Type-2 diabetes, inhibits the release of SGLT2 protein in the kidneys which reduces glucose reabsorption in blood and helps in lowering the blood sugar level of patients. Under the notified list the combination of empagliflozin 12.5mg and metformin hydrochloride 1000mg tablet of Corona Remedies is priced at ₹19.64, while a combination including linagliptin along with these active ingredients of Lupin is priced at ₹22.32. The notified retail prices excludes the applicable Goods and Services Tax (GST) and are applicable to the respective manufacturer and marketer specified in the list. As per a market research firm Pharmarack as of April 2025 the total market of empagliflozin and its related combination is valued around ₹745 crore. Of this, plain empagliflozin and its combination with linagliptin accounts for nearly 86 per cent of the total market. In FY25 empagliflozin plain tablets reported a Moving Annual Turnover of ₹337 crore, reflecting a market share of 45 per cent while its combination version with linagliptin had a MAT value of ₹308 crore and a market share of 41 per cent. Besides this the drug's other combinations such as empagliflozin and metformin reported an annual turnover of ₹102 crore with a 14 per cent market share. The retail price fixation exercise has been undertaken in the aftermath of the expiry of empagliflozin’s patent in March this year followed by a series of generic entrants in the market. In India, the drug patent was owned by Germany-based Boehringer Ingelheim and the drug was marketed under the brand name Jardiance. After the drug went off patent, companies like Alkem and Glenmark launched their generic versions under the brand names ‘Empanorm’ and ‘Glempa’ respectively. Besides them other major generic players like Mankind and USV also joined the fray. For patients, the development gave a major price relief as the generic versions are stated to cost around 80-90 per cent less than the patented version. As per the NPPA price list the innovator's version single tablet is priced at ₹53, whereas the other brands from the license holders Torrent, Cipla and Lupin are priced between ₹46-48 per tablet. While announcing the launch, Rajeev Juneja, Vice Chairman and Managing Director, Mankind Pharma said that, “the company will market its respective brand at ₹5.49 per tablet for the 10 mg variant and ₹9.90 per tablet for the 25 mg variant. The latest monthly progress report of Indian pharma market by Pharmarack suggests that as of April close to 147 brands from 37 companies have forayed in the empagliflozin plain and combinations market, reflecting a two-fold jump from the previous month status of 86 brands and 19 Companies. Under the provisions of Drugs (Prices Control) Order, 2013, the retail price of a new drug is fixed by NPPA and the applicant manufacturer and marketer, are required to sell the new drug within the notified price. By Abhijeet Singh ,

09 May 2025

·pharma.economictimes.indiatimes.com

NPPA sets Empagliflozin combos retail prices, as domestic brands initiate generic contest

New Delhi: As domestic brands in India began introducing their generic versions of key anti-diabetic medicine empagliflozin following the expiry of its patent, the National Pharmaceutical Pricing Authority (NPPA), has fixed the retail prices of the drug combinations and different dosage strengths. Issuing a gazette notification, the Ministry of Chemicals and Fertilizers and the country’s drug price regulator announced that “based on the decision of 132nd Authority meeting dated 29.4.2025 the authority has fixed retail prices of 84 formulations under Drugs (Prices Control) Order, 2013.” The price list attached with the official notification includes around 36 variants of empagliflozin, linagliptin and metformin hydrochloride Fixed-Dose Combinations (FDC) of various brands and manufacturers. Empagliflozin, indicated for Type-2 diabetes, inhibits the release of SGLT2 protein in the kidneys which reduces glucose reabsorption in blood and helps in lowering the blood sugar level of patients. Under the notified list the combination of empagliflozin 12.5mg and metformin hydrochloride 1000mg tablet of Corona Remedies is priced at ₹19.64, while a combination including linagliptin along with these active ingredients of Lupin is priced at ₹22.32. The notified retail prices excludes the applicable Goods and Services Tax (GST) and are applicable to the respective manufacturer and marketer specified in the list. As per a market research firm Pharmarack as of April 2025 the total market of empagliflozin and its related combination is valued around ₹745 crore. Of this, plain empagliflozin and its combination with linagliptin accounts for nearly 86 per cent of the total market. In FY25 empagliflozin plain tablets reported a Moving Annual Turnover of ₹337 crore, reflecting a market share of 45 per cent while its combination version with linagliptin had a MAT value of ₹308 crore and a market share of 41 per cent. Besides this the drug's other combinations such as empagliflozin and metformin reported an annual turnover of ₹102 crore with a 14 per cent market share. The retail price fixation exercise has been undertaken in the aftermath of the expiry of empagliflozin’s patent in March this year followed by a series of generic entrants in the market. In India, the drug patent was owned by Germany-based Boehringer Ingelheim and the drug was marketed under the brand name Jardiance. After the drug went off patent, companies like Alkem and Glenmark launched their generic versions under the brand names ‘Empanorm’ and ‘Glempa’ respectively. Besides them other major generic players like Mankind and USV also joined the fray. For patients, the development gave a major price relief as the generic versions are stated to cost around 80-90 per cent less than the patented version. As per the NPPA price list the innovator's version single tablet is priced at ₹53, whereas the other brands from the license holders Torrent, Cipla and Lupin are priced between ₹46-48 per tablet. While announcing the launch, Rajeev Juneja, Vice Chairman and Managing Director, Mankind Pharma said that, “the company will market its respective brand at ₹5.49 per tablet for the 10 mg variant and ₹9.90 per tablet for the 25 mg variant. The latest monthly progress report of Indian pharma market by Pharmarack suggests that as of April close to 147 brands from 37 companies have forayed in the empagliflozin plain and combinations market, reflecting a two-fold jump from the previous month status of 86 brands and 19 Companies. Under the provisions of Drugs (Prices Control) Order, 2013, the retail price of a new drug is fixed by NPPA and the applicant manufacturer and marketer, are required to sell the new drug within the notified price. By Abhijeet Singh ,

09 May 2025

·pharma.economictimes.indiatimes.com

Generic versions of key diabetic drug in market double in a month

New Delhi: In less than two months after diabetes drug Empagliflozin went off patent, Indian branded generic players have crowded the market with their versions of the product leading to a month-on-month doubling in the number of players and brands flooding the market in April. Nearly 147 brands of the drug and 37 companies are in the market now, up from 86 brands and 19 companies in March, according to data from industry tracker and market researcher PharmaTrac. Doctors said that an increasing number of anti-diabetic drugs going off patent-with Empagliflozin being the latest-is good for patients and medical practitioners as it makes anti diabetes drugs more affordable in India where cases of diabetes are rising. Empagliflozin-which was Boehringer Ingelheim's innovator drug sold under the brand name Jardiance-went off patent mid-March. It is used to improve glucose control in people with Type 2 diabetes. "With almost 150 brands and 40 companies jumping in the Empagliflozin off patent opportunity and volume sales picking up steeply in the last two months, every player in the IPM (Indian pharmaceutical market) looks like geared up to make the most of this opportunity," said Sheetal Sapale, vice president, commercial, PharmaTrac. "Most of the innovator molecules (used to treat Type 2 diabetes) in SGLT 2 (Sodium-Glucose Co-Transporter-2) and DPP4 i (Dipeptidyl peptidase-4 inhibitors) have gone off patent... creating many affordable options available to eligible Indian masses through branded generics ," she added. Empagliflozin is an SGLT-2 inhibitor . Others in the same group include dapagliflozin-whose patent expired a couple years ago leading to nearly 200 generic brands coming into the market. Companies such as Alkem Laboratories , Glenmark Pharmaceuticals and Mankind Pharma launched their versions of Empagliflozin, and slashed prices to about ₹5 per unit, which is 80-90 per cent lower than the innovator's prices. "Ever since dapagliflozin has gone off patent, many more people have access to it has become cheaper. Empagliflozin is also similar to it...it's a good medicine for sugar, gives some protection to the heart and kidney too," said Dr David Chandy, director-endocrinology & diabetology at Sir H N Reliance Foundation Hospital and Research Centre. More such molecules going off patent increases the reach to larger populations. "Earlier when only the innovators had these molecules, maybe 2-5 per cent of India's diabetic population could afford it, now the entire diabetic population can afford it," said Chandy. Empagliflozin is a ₹745 crore market today with plains contributing to almost 45 per cent in terms of value as well as quantity. Empagliflozin plain and Empagliflozin plus Linagliptin contribute nearly 80 per cent of this. "In the long-term, more and more affordable medication options are good for patients with the cases of diabetes spiralling in the country and doctors have more ammunition or options for treatment now compared to 5-10 years back," said Chandy. "What will be interesting in the diabetes scenario is that in the next six months, once semaglutide goes off patent, there will be a paradigm shift for diabetes treatment once it is available at a low price," he said. By Rica Bhattacharyya ,

100 Deals associated with Linagliptin

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D09566	Linagliptin	A10BH05	DB08882

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Diabetes Mellitus, Type 2	United States	Boehringer Ingelheim Pharmaceuticals, Inc.	02 May 2011

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Stiffness	Phase 3	Netherlands	Boehringer Ingelheim GmbH	01 Mar 2014
Albuminuria	Phase 3	United States	Eli Lilly & Co.	01 Feb 2013
Albuminuria	Phase 3	United States	Boehringer Ingelheim GmbH	01 Feb 2013
Albuminuria	Phase 3	Japan	Eli Lilly & Co.	01 Feb 2013
Albuminuria	Phase 3	Japan	Boehringer Ingelheim GmbH	01 Feb 2013
Albuminuria	Phase 3	Canada	Boehringer Ingelheim GmbH	01 Feb 2013
Albuminuria	Phase 3	Canada	Eli Lilly & Co.	01 Feb 2013
Albuminuria	Phase 3	Denmark	Boehringer Ingelheim GmbH	01 Feb 2013
Albuminuria	Phase 3	Denmark	Eli Lilly & Co.	01 Feb 2013
Albuminuria	Phase 3	Finland	Boehringer Ingelheim GmbH	01 Feb 2013

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03194945 (Literature) Manual	Phase 4	Diabetes Mellitus, Type 2	412	Linagliptin plus Metformin	haosgechin(gbigklxvfw) = snclgkcpfd kqkstkibvf (duetafojiu ) View more	Positive	15 Oct 2024
				Linagliptin	haosgechin(gbigklxvfw) = xnbrqjaeoq kqkstkibvf (duetafojiu ) View more
ATS2024	Not Applicable	-	-	Linagliptin 5 mg	vqsjpbrsvq(bmognsmahm) = Severe hyponatremia (serum sodium concentration below120 mEq/L) can cause seizure, coma, and death. Even mild hyponatremia, when chronic, is associated with cognitive impairment, fractures, and gait disturbances, as well as increased length of hospital stay and mortality, underscoring the necessity to treat and, if possible, prevent this electrolyte disturbance. tkychaigmo (lrhcaccvrn ) View more	-	19 May 2024
				Insulin glargine 8 units nightly
NCT03470454 (Pubmed \| Ren Fail)	Not Applicable	Acute Kidney Injury	800	N-acetyl cysteine and saline	pvwjafhlpy(qcmbdddzih) = ougvgbmxdj awpoirlqbf (agvwrwhhid )	-	31 Dec 2023
				Allopurinol	pvwjafhlpy(qcmbdddzih) = imrizbpdtt awpoirlqbf (agvwrwhhid )
NCT04564872 (HSK7653, EASD2023)	Phase 3	Diabetes Mellitus, Type 2 Add-on	-	HSK7653 10mg	dugjmfmxkk(zibekfssnu) = irksrnovri mabmzcnxxw (slsfhamolc, -1.08 to -0.83)	Positive	03 Oct 2023
				HSK7653 25mg	dugjmfmxkk(zibekfssnu) = qsmlaobhtd mabmzcnxxw (slsfhamolc, -1.12 to -0.87)
ADA2023	Not Applicable	Prediabetic State	658	Metformin monotherapy	ltjglvrwjn(euwdrxcvpp) = kzuaczfbdc wubkpideim (uuprscsvle ) View more	-	20 Jun 2023
				Linagliptin monotherapy	lbcrocphqf(tmvnkynutj) = stsehcizxw igijocevnv (xpeevgwbbr )
NCT02372630 (1971, CTgov)	Phase 4	Insulin Resistance \| Inflammation \| stress oxidative ... View more	40	Placebo (Placebo)	huodaamplj(jnsnhoohfo) = pgmdtykjjm obzfzajeuu (rcsitxpzno, 0.148) View more	-	21 Feb 2023
				Linagliptin (Linagliptin 5mg Per Day)	huodaamplj(jnsnhoohfo) = cjhxgfjzlm obzfzajeuu (rcsitxpzno, 0.129) View more
NCT02467478 (CTgov)	Phase 4	Diabetes Mellitus, Type 2 \| Renal Insufficiency \| Chronic Kidney Diseases	31	Placebo (Placebo)	nbsawrcosz(dyndkgpfcd) = qsjuixboji gjmihlhqyd (ryfboojfvl, 1.11) View more	-	19 Jan 2023
				Linagliptin (Linagliptin)	nbsawrcosz(dyndkgpfcd) = uwnkddivfq gjmihlhqyd (ryfboojfvl, 2.80) View more
ADA2022	Not Applicable	Diabetes Mellitus, Type 2	100	Linagliptin	zkufmwebus(kunudpsbyn) = exyvlhzjvq qexlzjdall (nlvigskflv )	-	01 Jun 2022
				Sitagliptin	zkufmwebus(kunudpsbyn) = jjmhdbtfjy qexlzjdall (nlvigskflv )
NCT01650259 (Pubmed \| Expert Opin Drug Saf)	Not Applicable	Diabetes Mellitus, Type 2	4,876	linagliptin (BMI <25 kg/m2)	yhuhwgkgdl(exsrsnjfri) = yuhotjcill zxygkvmqkz (gxennttmez ) View more	-	14 Apr 2022
				linagliptin (BMI 25 to <30 kg/m2)	yhuhwgkgdl(exsrsnjfri) = orguuqsild zxygkvmqkz (gxennttmez ) View more
NCT04542213 (Pubmed \| Sci Rep)	Phase 3	COVID-19	73	Linagliptin + insulin	wiwflrdvin(sqhvkryeoy) = No major side effects were observed djpbuipgcd (ncpmfdoofe )	Positive	11 Jan 2022
				Insulin alone